NeoGenomics: CEO transition and preliminary Q3 2026 results

What happened

• The filing says the board approved the appointment of Warren Stone as chief executive officer and member of the board, effective Jan 4, 2027. In connection with that appointment, the filing says Tony Zook will transition from chief executive officer to executive chairman, effective Jan 4, 2027.
• The filing also says the company issued a press release on Oct 5, 2026 that included certain preliminary financial results as of and for the quarter ended Sep 30, 2026.

Key details

• Warren Stone is age 54 and joined the company in Nov 2022; he served as president, clinical services, was chief commercial officer in Apr 2024, and was named president & chief operating officer in Apr 2025.
• The filing says the company and Mr. Stone entered into an amended and restated employment agreement effective Jan 4, 2027 providing a base salary of $850,000 per year, a target annual incentive bonus of 100% of base salary, and annual equity incentive awards beginning in FY 2027 with an aggregate target value of approximately $8,000,000.
• The filing says severance if Mr. Stone is terminated by the company without cause or he terminates for good reason generally equals 1 times base salary and 1 times target bonus, plus 12 months of COBRA premiums if elected and accelerated vesting for time-based equity that would vest within 12 months; in the 24 months following or the 3 months preceding a change in control the filing says severance equals 2 times base salary and 1 times target bonus and accelerated vesting of all time-based equity (options remain exercisable for 1 year or until expiration).
• The filing says the board approved an amendment to the bylaws, effective Sep 30, 2026, increasing the maximum board size from 10 to 11 directors.

Why it may matter

• The filing reports Item 5.02 (departure of directors or certain officers; election of directors) for the CEO transition and the Stone employment agreement, Item 5.03 (amendments to articles of incorporation or bylaws) for the board size increase, and Item 2.02 (results of operations and financial condition) for the preliminary quarter results disclosed in the Oct 5, 2026 press release. This filing does not show why the insider traded or why the company acted.